

Product guide

All products shown at actual size.



OASIS®
Wound Matrix

OASIS® ULTRA
Tri-Layer Matrix

Ordering information

OASIS ULTRA Tri-Layer Matrix

Product code	Product description	Box quantity
8213-0000-16	3 x 3.5cm fenestrated	5 sheets
8213-0000-18	3 x 7cm fenestrated	5 sheets
8213-0000-13	5 x 7cm meshed	5 sheets
8213-0000-09	7 x 10cm meshed	5 sheets
8213-0000-11	7 x 20cm meshed	5 sheets

OASIS Wound Matrix

Product code	Product description	Box quantity
8213-1000-33	3 x 3.5cm fenestrated	10 sheets
8213-1000-37	3 x 7cm fenestrated	10 sheets



Nationally selected by VA as a topical skin substitute of choice (VA Prosthetics Biologics and Biologic Implant Award).

All sizes of OASIS® Wound Matrix and OASIS ULTRA Tri-Layer Matrix are now available on the VHA MSPV-NG catalog.

OASIS ULTRA Tri-Layer Matrix

7 x 20cm
140cm²
meshed
8213-0000-11

7 x 10cm
70cm²
meshed
8213-0000-09

3 x 7cm
21cm²
fenestrated
8213-1000-37

5 x 7cm
35cm²
meshed
8213-0000-13

3 x 7cm
21cm²
fenestrated
8213-0000-18

3 x 3.5cm
10.5cm²
fenestrated
8213-1000-33

3 x 3.5cm
10.5cm²
fenestrated
8213-0000-16

Visit www.oasismatrix.com for more information or order OASIS Matrix by calling 1-800-441-8227.

OASIS® Matrix Products

Simple ECM Solutions for your wound management needs



24-month shelf life
from date of manufacture



Easy storage
(room temperature)



No advance preparation
needed for use

Proven results in multiple clinical trials with multiple wound types*

Diabetic ulcers

54% achieved complete wound closure at 12 weeks in OASIS Wound Matrix + Standard of Care (SOC) group vs **32% of patients** receiving SOC alone (p=0.021).¹

4x less costly per patient with OASIS Wound Matrix + SOC vs Dermagraft™ + SOC over a 12-week period.^{2†}

Venous ulcers

55% achieved complete wound closure at 12 weeks in OASIS Wound Matrix + SOC group vs **34% of wounds** receiving SOC alone (p=0.0196).³

Chronic vascular ulcers

80% achieved complete wound closure at 8 weeks in OASIS + SOC vs 65% in petrolatum-treated ulcers (p<0.05)⁴

*See references for definition of standard of care (SOC) as defined in each clinical trial.

†Costs based on the 2008 costs of materials.

For any product-related questions, please contact Customer Care at **1-800-441-8227** or visit **www.oasismatrix.com** to learn more.



Contraindications:

This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material. This device is not indicated for use in third-degree burns.

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use.

References: 1. Cazzell SM, Lange DL, Dickerson JE Jr, Slade HB. The management of diabetic foot ulcers with porcine small intestine submucosa tri-layer matrix: A randomized controlled trial. *Adv Wound Care.* 2015;4:711-718. 2. Landsman A, Roukis TS, DeFronzo DJ, et al. Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers? *Wounds.* 2008;20:111-116. 3. Mostow EN, Haraway GD, Dalsing M, et al. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. *J Vasc Surg.* 2005;41:837-843. 4. Romanelli M, Dini V, Bertone MS. Randomized Comparison of OASIS Wound Matrix versus Moist Wound Dressing in the Treatment of Difficult-to-Heal Wounds of Mixed Arterial/Venous Etiology. *Adv Skin Wound Care.* 2010; 23:34-38.

Manufactured by:

Cook Biotech, Inc.
1425 Innovation Place
West Lafayette, IN 47906

Distributed by:

Advanced Wound Management
Smith & Nephew, Inc.
Fort Worth, TX 76109
USA

www.smith-nephew.com
www.oasismatrix.com
Customer Care Center:
T 800 441-8227
T 817 900-4000
F 817 900-4100

©2018 Smith & Nephew, Inc.
OASIS is a registered trademark of
Cook Biotech, Inc. All trademarks
acknowledged.
OMPE2-13865-1218

Supporting healthcare professionals for over 150 years.